Bronquiectasia

Referências

Principais artigos

Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950;5:233-247.Texto completo  Resumo

Rosen MJ. Chronic cough due to bronchiectasis. ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1_Suppl):122S-131S.Texto completo  Resumo

Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019 Jan;74(suppl 1):1-69.Texto completo  Resumo

Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. Resumo

Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013 Mar 27;309(12):1260-7.Texto completo  Resumo

Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85.Texto completo  Resumo

Artigos de referência

1. Laennec RT. A treatise on the disease of the chest. Forbes J, trans. New York, NY: Macmillan (Hafner Press);1962:78.

2. Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950;5:233-247.Texto completo  Resumo

3. Rosen MJ. Chronic cough due to bronchiectasis. ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1_Suppl):122S-131S.Texto completo  Resumo

4. Barker AF. Bronchiectasis. New Engl J Med. 2002;346:1383-1393. Resumo

5. Liebow AA, Hales MR, Lindskog GE. Enlargement of the bronchial arteries, and their anastomoses with the pulmonary arteries in bronchiectasis. Am J Pathol. 1949;25:211-231.Texto completo  Resumo

6. Weyker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12:205.

7. Seitz AE, Olivier KN, Adjemian J, et al. Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. Chest. 2012 Aug;142(2):432-39.Texto completo  Resumo

8. Snell N, Gibson J, Jarrold I, et al. Epidemiology of bronchiectasis in the UK: findings from the British Lung Foundation's 'Respiratory Health of the Nation' project. Respir Med. 2019 Oct - Nov;158:21-23. Resumo

9. Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child. 2005 Jul;90(7):737-40. Resumo

10. McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest. 2012 Jul;142(1):159-67. Resumo

11. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long term study assessing the factors influencing survival. Eur Respir J. 2009 Oct;34(4):843-9. Resumo

12. Gao YH, Guan WJ, Liu SX, et al. Aetiology of bronchiectasis in adults: a systematic literature review. Respirology. 2016 Nov;21(8):1376-83.Texto completo  Resumo

13. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med. 2000 Oct;162(4 Pt 1):1277-84. Resumo

14. Cole PJ. Host microbe relationships in chronic respiratory infection. Respiration. 1989;55(suppl 1):5-8. Resumo

15. Morrissey BM. Pathogenesis of bronchiectasis. Clin Chest Med. 2007;28:289-296. Resumo

16. Burgel PR, Montani D, Danel C, et al. A morphometric study of mucins and small airway plugging in cystic fibrosis. Thorax. 2007;62:153-161. Resumo

17. Rodman DM. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Resp Crit Care Med. 2005 Mar 15;171(6):621-6. Resumo

18. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies. N Engl J Med. 1995 Aug 17;333(7):431-40. Resumo

19. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999 Jul;92(1):34-48. Resumo

20. Hartl D, Latzin P, Zissel G, et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Am J Respir Crit Care Med. 2006 Jun 15;173(12):1370-6.Texto completo  Resumo

21. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med. 1989 Sep 28;321(13):863-8. Resumo

22. Elborn JS. Cystic fibrosis. Lancet. 2016 Nov 19;388(10059):2519-31. Resumo

23. Lucas JS, Barbato A, Collins SA, et al. European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia. Eur Respir J. 2017 Jan 4;49(1):1601090.Texto completo  Resumo

24. Le Mauviel L. Primary ciliary dyskinesia. West J Med. 1991 Sep;155(3):280-3.Texto completo  Resumo

25. Shapiro AJ, Davis SD, Polineni D, et al. Diagnosis of primary ciliary dyskinesia. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-e39.Texto completo  Resumo

26. Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med. 2013 Oct 15;188(8):913-22.Texto completo  Resumo

27. Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha(1)-antitrypsin alleles in patients with bronchiectasis. Chest. 2000 Feb;117(2):415-9.Texto completo  Resumo

28. McMahon MJ, Swinson DR, Shettar S, et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis. 1993 Nov;52(11):776-9. Resumo

29. Camus P, Colby TV. The lung in inflammatory bowel disease. Eur Respir J. 2000 Jan;15(1):5-10.Texto completo  Resumo

30. Silva JR, Jones JA, Cole PJ, et al. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax. 1989 Aug;44(8):668-73.Texto completo  Resumo

31. Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med. 2008 Nov 15;178(10):1066-74.Texto completo  Resumo

32. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995 Oct;108(4):955-61.Texto completo  Resumo

33. Farrell PM, White TB, Ren CL, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr. 2017 Feb;181S:S4-S15.e1.Texto completo  Resumo

34. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society guideline for bronchiectasis in adults. Thorax. 2019 Jan;74(suppl 1):1-69.Texto completo  Resumo

35. Paris K, Sorensen RU. Assessment and clinical interpretation of polysaccharide antibody responses. Ann Allergy Asthma Immunol. 2007 Nov;99(5):462-4. Resumo

36. Verghese A. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. Arch Intern Med. 1994 Sep 26;154(18):2086-91. Resumo

37. Shapiro AJ, Josephson M, Rosenfeld M, et al. Accuracy of nasal nitric oxide measurement as a diagnostic test for primary ciliary dyskinesia. A systematic review and meta-analysis. Ann Am Thorac Soc. 2017 Jul;14(7):1184-96.Texto completo  Resumo

38. Hansell DM. Bronchiectasis. Radiol Clin North Am. 1998 Jan;36(1):107-28. Resumo

39. Hansell DM. Imaging of diseases of the chest. 4th ed. Philadelphia, PA: Elsevier Mosby; 1995.

40. Konstan MW, Morgan WJ, Butler SM, et al.; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr. 2007 Aug;151(2):134-9. Resumo

41. Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007 Jun;42(6):525-32. Resumo

42. Rivera M. Pseudomonas aeruginosa mucoid strain. Its significance in adult chest diseases. Am Rev Respir Dis. 1982 Nov;126(5):833-6. Resumo

43. Moss RB. Fungi in cystic fibrosis and non-cystic fibrosis bronchiectasis. Semin Respir Crit Care Med. 2015 Apr;36(2):207-16. Resumo

44. Woodworth MH, Saullo JL, Lantos PM, et al. Increasing Nocardia incidence associated with bronchiectasis at a tertiary care center. Ann Am Thorac Soc. 2017 Mar;14(3):347-54.Texto completo  Resumo

45. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005 Jun 25-Jul 1;365(9478):2225-36. Resumo

46. Hill AT, Barker AF, Bolser DC, et al. Treating cough due to non-CF and CF bronchiectasis with nonpharmacological airway clearance: CHEST Expert Panel Report. Chest. 2018 Apr;153(4):986-93.Texto completo  Resumo

47. Lee AL, Burge AT, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2015 Nov 23;(11):CD008351.Texto completo  Resumo

48. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009 Nov;34(5):1086-92. Resumo

49. Nicolson CH, Stirling RG, Borg BM, et al. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med. 2012 May;106(5):661-7. Resumo

50. Reeves EP, Williamson M, O'Neill SJ, et al. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1517-23.Texto completo  Resumo

51. Bilton D, Daviskas E, Anderson SD, et al; B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest. 2013 Jul;144(1):215-25.Texto completo  Resumo

52. Tarrant BJ, Le Maitre C, Romero L, et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: a systematic review and meta-analysis. Respirology. 2017 Aug;22(6):1084-92.Texto completo  Resumo

53. Bilton D, Tino G, Barker AF, et al; B-305 Study Investigators. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial. Thorax. 2014 Dec;69(12):1073-9. Resumo

54. Hart A, Sugumar K, Milan SJ, et al. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2014 May 12;(5):CD002996.Texto completo  Resumo

55. Crasafulli E, Colettu O, Costi S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day prospective, parallel, open- label, pilot study. Clin Ther. 2007 Sep;29(9):2001-9. Resumo

56. Wilkinson M, Sugumar K, Milan SJ, et al. Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2014 May 2;(5):CD001289.Texto completo  Resumo

57. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax. 2005 Nov;60(11):943-8. Resumo

58. Lee AL, Hill CJ, McDonald CF, et al. Pulmonary rehabilitation in individuals with non-cystic fibrosis bronchiectasis: a systematic review. Arch Phys Med Rehabil. 2017 Apr;98(4):774-82.e1. Resumo

59. Onen ZP, Gulbay BE, Sen E, et al. Analysis of the factors related to mortality in patients with bronchiectasis. Respir Med. 2007 Jul;101(7):1390-7. Resumo

60. White L, Mirrani G, Grover M, et al. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med. 2012 Mar;106(3):356-60.Texto completo  Resumo

61. Chalmers JD, Smith MP, McHugh BJ, et al. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012 Oct 1;186(7):657-65. Resumo

62. Murray MP, Govan JR, Doherty CJ, et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011 Feb 15;183(4):491-9. Resumo

63. O'Donnell AE. Bronchiectasis: which antibiotics to use and when? Curr Opin Pulm Med. 2015 May;21(3):272-7. Resumo

64. Paredes Aller S, Quittner AL, Salathe MA, et al. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials. Expert Rev Respir Med. 2018 Sep;12(9):769-82. Resumo

65. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013 Mar 27;309(12):1251-9. Resumo

66. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA. 2013 Mar 27;309(12):1260-7.Texto completo  Resumo

67. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):660-7. Resumo

68. Kelly C, Chalmers JD, Crossingham I, et al. Macrolide antibiotics for bronchiectasis. Cochrane Database Syst Rev. 2018 Mar 15;3:CD012406.Texto completo  Resumo

69. Goyal V, Grimwood K, Byrnes CA, et al. Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial. Lancet. 2018 Oct 6;392(10154):1197-206. Resumo

70. Choo JM, Abell GCJ, Thomson R3, et al. Impact of long-term erythromycin therapy on the oropharyngeal microbiome and resistance gene reservoir in non-cystic fibrosis bronchiectasis. mSphere. 2018 Apr 18;3(2):e00103-18.Texto completo  Resumo

71. Hnin K, Nguyen C, Carson KV, et al. Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults. Cochrane Database Syst Rev. 2015 Aug 13;(8):CD001392.Texto completo  Resumo

72. Chang KC, Leung CC, Yew WW, et al. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur Respir J. 2010 Mar;35(3):606-13. Resumo

73. European Medicines Agency. Quinolone- and fluoroquinolone-containing medicinal products. Mar 2019 [internet publication].Texto completo

74. US Food and Drug Administration. FDA drug safety communication. FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. Dec 2018 [internet publication].Texto completo

75. US Food and Drug Administration. FDA drug safety communication. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].Texto completo

76. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017 Sep 9;50(3):1700629.Texto completo  Resumo

77. Tsang KW, Tan KC, Ho PL, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005 Mar;60(3):239-43. Resumo

78. Kapur N, Petsky HL, Bell S, et al. Inhaled corticosteroids for bronchiectasis. Cochrane Database Syst Rev. 2018 May 16;5:CD000996.Texto completo  Resumo

79. Brode SK, Campitelli MA, Kwong JC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017 Sep 20;50(3):1700037.Texto completo  Resumo

80. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014 Mar 1;189(5):576-85.Texto completo  Resumo

81. Ellis HC, Cowman S, Fernandes M, et al. Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study. Eur Respir J. 2016 Feb;47(2):482-9. Resumo

82. McDonnell MJ, Aliberti S, Goeminne PC, et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts. Thorax. 2016 Dec;71(12):1110-8.Texto completo  Resumo

83. Zhang P, Jiang G, Ding J, et al. Surgical treatment of bronchiectasis: a retrospective analysis of 790 patients. Ann Thorac Surg. 2010 Jul;90(1):246-50. Resumo

84. Bagheri R, Haghi SZ, Fattahi Massoum SH, et al. Surgical management of bronchiectasis: analysis of 277 patients. Thorac Cardiovasc Surg. 2010 Aug;58(5):291-4. Resumo

85. Scheinberg P, Shore E; PC-TNDS-008 Study Group. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005 Apr;127(4):1420-6.Texto completo  Resumo

86. Wilson R, Welte T, Polverino E, et al. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013 May;41(5):1107-15.Texto completo  Resumo

87. Serisier DJ, Bilton D, De Soyza A, et al; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax. 2013 Sep;68(9):812-7.Texto completo  Resumo

88. De Soyza A, Aksamit T, Bandel TJ, et al. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018 Jan 25;51(1):1702052.Texto completo  Resumo

89. Aksamit T, De Soyza A, Bandel TJ, et al. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis. Eur Respir J. 2018 Jan 25;51(1):1702053.Texto completo  Resumo

90. Ailiyaer Y, Wang X, Zhang Y, et al. A prospective trial of nebulized amikacin in the treatment of bronchiectasis exacerbation. Respiration. 2018;95(5):327-33.Texto completo  Resumo

91. Sibila O, Laserna E, Shoemark A, et al. Airway bacterial load and inhaled antibiotic response in bronchiectasis. Am J Respir Crit Care Med. 2019 Jul 1;200(1):33-41. Resumo

92. Orriols R, Hernando R, Ferrer A, et al. Eradication therapy against Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiration. 2015;90(4):299-305.Texto completo  Resumo

93. Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2017 Sep 27;9:CD011699.Texto completo  Resumo

94. D'Abrosca F, Garabelli B, Savio G, et al. Comparing airways clearance techniques in chronic obstructive pulmonary disease and bronchiectasis: positive expiratory pressure or temporary positive expiratory pressure? A retrospective study. Braz J Phys Ther. 2017 Jan - Feb;21(1):15-23.Texto completo  Resumo

95. Tambascio J, de Souza HCD, Martinez R, et al. Effects of an airway clearance device on inflammation, bacteriology, and mucus transport in bronchiectasis. Respir Care. 2017 Aug;62(8):1067-74.Texto completo  Resumo

96. Kamimura M, Kameyama N, Homma C, et al. A new method for enhanced expectoration of sputum by vibratory stimulation of the cervical trachea. Respir Investig. 2017 Jul;55(4):276-82. Resumo

97. Silva YR, Greer TA, Morgan LC, et al. A comparison of 2 respiratory devices for sputum clearance in adults with non-cystic fibrosis bronchiectasis. Respir Care. 2017 Oct;62(10):1291-7.Texto completo  Resumo

98. Bedi P, Chalmers JD, Graham C, et al. A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with pseudomonas aeruginosa: a proof of concept study. Chest. 2017 Aug;152(2):368-78.Texto completo  Resumo

99. Keistinen T, Saynajakangas O, Tuuponen T, et al. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J. 1997 Dec;10(12):2784-7.Texto completo  Resumo

100. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007 Nov;132(5):1565-72. Resumo

101. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest. 2005 Aug;128(2):739-45.Texto completo  Resumo

102. Fartoukh M, Khalil A, Louis L, et al. An integrated approach to diagnosis and management of severe haemoptysis in patients admitted to the intensive care unit: a case series from a referral center. Respir Res. 2007 Feb 15;8:11.Texto completo  Resumo

103. Serasli E, Kalpakidis V, Iatrou K, et al. Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes. Int Angiol. 2008 Aug;27(4):319-28. Resumo

104. Panda A, Bhalla AS, Goyal A. Bronchial artery embolization in hemoptysis: a systematic review. Diagn Interv Radiol. 2017 Jul-Aug;23(4):307-17.Texto completo  Resumo

105. Chen YF, Lin HH, Lin CS, et al. Bronchiectasis and increased risk of ischemic stroke: a nationwide population-based cohort study. Int J Chron Obstruct Pulmon Dis. 2017 May 10;12:1375-83.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal